Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mechanism of tamoxifen resistance. In recent years, with progress in research into the protective autophagy of drug-resistant cells and cell cycle regulators, major breakthroughs have been made in research on tamoxifen resistance. For a better understanding of the mechanism of tamoxifen resistance, protective autophagy, cell cycle regulators, and some transcription factors and enzymes regulating the expression of the estrogen receptor are summarized in this review. In addition, recent progress in reducing resistance to tamoxifen is reviewed. Finally, we discuss the possible research directions into tamoxifen resistance in the future to provide assistance for the clinical treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900 · cited 1×
“Based on these mechanisms, scientists have previously proposed many methods to overcome drug resistance, such as the cyclindependent kinase (CDK) 4/6 inhibitors palbociclib and ribociclib (Finn et al., 2015; Cristofanilli et al., 2016; Hortobagyi et al., 2016).”
Background
Research works printed but not linked: 88
- Ali, 2016, Current management strategies in breast cancer by targeting key altered molecular players, Front. Oncol., 6, 45, 10.3389/fonc.2016.00045 · DOI
- Antonioli, 2017, Emerging mechanisms in initiating and terminating autophagy, Trends Biochem. Sci., 42, 28, 10.1016/j.tibs.2016.09.008 · DOI · Paper page
- Binkhorst, 2012, Individualization of tamoxifen treatment for breast carcinoma, Clin. Pharmacol. Ther., 92, 431, 10.1038/clpt.2012.94 · DOI
- Block, 2012, Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells, Int. J. Oncol., 41, 1845, 10.3892/ijo.2012.1591 · doi:10.3892/ijo.2012.1591
- Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
- Cheng, 2017, Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells, Oncotarget, 8, 30252, 10.18632/oncotarget.16325 · DOI
- Cheng, 2019, Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM, Breast Cancer, 26, 766, 10.1007/s12282-019-00980-5 · DOI
- Choi, 2016, Co-treatment of LY294002 or MK-2206 with AZD5363 attenuates AZD5363-induced increase in the level of phosphorylated AKT, Ar, 36, 5849, 10.21873/anticanres.11170 · doi:10.21873/anticanres.11170
- Choi, 2018, Role of RBP2-induced ER and IGF1R-ErbB signaling in tamoxifen resistance in breast cancer, J. Natl. Cancer Inst., 110, 400, 10.1093/jnci/djx207 · DOI
- Cook, 2011, Autophagy and endocrine resistance in breast cancer, Expet Rev. Anticancer Ther., 11, 1283, 10.1586/era.11.111 · DOI · Paper page
- Cristofanilli, 2016, Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial, Lancet Oncol., 17, 425, 10.1016/S1470-2045(15)00613-0 · DOI · Paper page
- Das, 2019, Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer, Biochim. Biophys. Acta Mol. Cell Res., 1866, 1004, 10.1016/j.bbamcr.2019.03.004 · DOI
- Elias, 2015, Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy, Oncogene, 34, 1919, 10.1038/onc.2014.138 · DOI
- Ferraiuolo, 2017, The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance, Oncotarget, 8, 23337, 10.18632/oncotarget.15578 · DOI
- Gao, 2018, LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway, Nat. Commun., 9, 4180, 10.1038/s41467-018-06309-8 · DOI
- Giordano, 2011, Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression, Oncogene, 30, 4129, 10.1038/onc.2011.124 · DOI
- Gong, 2018, BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen-resistant breast cancer, Clin. Canc. Res., 24, 3681, 10.1158/1078-0432.CCR-17-2259 · DOI
- Gonzalez-Malerva, 2011, High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy, Proc. Natl. Acad. Sci. USA, 108, 2058, 10.1073/pnas.1018157108 · DOI
- Guney Eskiler, 2018, Solid lipid nanoparticles: reversal of tamoxifen resistance in breast cancer, Eur. J. Pharmaceut. Sci., 120, 73, 10.1016/j.ejps.2018.04.040 · DOI
- Gwak, 2017, Expression of embryonal stem cell transcription factors in breast cancer: oct4 as an indicator for poor clinical outcome and tamoxifen resistance, Oncotarget, 8, 36305, 10.18632/oncotarget.16750 · DOI
- He, 2019, The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells, Oncogene, 38, 5551, 10.1038/s41388-019-0817-3 · DOI
- Heckler, 2014, ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer, FEBS J., 281, 2431, 10.1111/febs.12797 · DOI
- Hosford, 2014, Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways, Pharmgenomics Pers Med, 7, 203, 10.2147/PGPM.S52762 · DOI · Paper page
- Huang, 2019, Targeting Pin1 by all-trans retinoic acid (ATRA) overcomes tamoxifen resistance in breast cancer via multifactorial mechanisms, Front. Cell Dev. Biol., 7, 322, 10.3389/fcell.2019.00322 · DOI
- Ito, 2012, Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer, Breast Canc. Res. Treat., 133, 145, 10.1007/s10549-011-1731-8 · doi:10.1007/s10549-011-1731-8
- Jeong, 2019, EGFR is a therapeutic target in hormone receptor-positive breast cancer, Cell. Physiol. Biochem., 53, 805, 10.33594/000000174 · doi:10.33594/000000174
- Jeselsohn, 2017, Embryonic transcription factor SOX9 drives breast cancer endocrine resistance, Proc. Natl. Acad. Sci. USA, 114, E4482, 10.1073/pnas.1620993114 · DOI
- Jia, 2018, KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer, Cell. Signal., 42, 165, 10.1016/j.cellsig.2017.09.025 · DOI
- Jiang, 2020, Dying tumor cell-derived exosomal miR-194-5p potentiates survival and repopulation of tumor repopulating cells upon radiotherapy in pancreatic cancer, Mol. Canc., 19, 68, 10.1186/s12943-020-01178-6 · DOI
- Jögi, 2019, Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer, PLoS One, 14, e0226150, 10.1371/journal.pone.0226150 · DOI · Paper page
- John, 2008, Regulation of estrogenic effects by beclin 1 in breast cancer cells, Canc. Res., 68, 7855, 10.1158/0008-5472.CAN-07-5875 · DOI
- Karlsson, 2019, PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer, J. Canc. Res. Clin. Oncol., 145, 599, 10.1007/s00432-018-2810-6 · doi:10.1007/s00432-018-2810-6
- Kim, 2006, Cancer's molecular sweet tooth and the warburg effect: figure 1, Canc. Res., 66, 8927, 10.1158/0008-5472.CAN-06-1501 · DOI · Paper page
- Kim, 2015, Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells, Oncol. Rep., 34, 1613, 10.3892/or.2015.4116 · DOI
- Kulkoyluoglu-Cotul, 2019, Combined targeting of estrogen receptor alpha and XPO1 prevent akt activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance, Cancers, 11, 479, 10.3390/cancers11040479 · DOI
- Kumar, 2018, N-desmethyl tamoxifen and quercetin-loaded multiwalled CNTs: a synergistic approach to overcome MDR in cancer cells, Mater. Sci. Eng. C, 89, 274, 10.1016/j.msec.2018.03.033 · DOI
- Kuo, 2013, SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein, Oncol. Rep., 30, 125, 10.3892/or.2013.2470 · DOI
- Lee, 2018, MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells, Autophagy, 14, 812, 10.1080/15548627.2017.1388476 · DOI
- Lee, 2017, Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell, Free Radic. Biol. Med., 110, 280, 10.1016/j.freeradbiomed.2017.06.017 · DOI
- Li, Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer, Canc. Sci., 111, 47, 10.1111/cas.14230 · DOI · Paper page
- Li, ERalpha36 as a potential therapeutic target for tamoxifen-resistant breast cancer cell line through EGFR/ERK signaling pathway, Canc. Manag. Res., 12, 265, 10.2147/CMAR.S226410 · DOI
- Li, 2016, Brachyury promotes tamoxifen resistance in breast cancer by targeting SIRT1, Biomed. Pharmacother., 84, 28, 10.1016/j.biopha.2016.09.011 · doi:10.1016/j.biopha.2016.09.011
- Li, 2019, Repositioning aspirin to treat lung and breast cancers and overcome acquired resistance to targeted therapy, Front Oncol, 9, 1503, 10.3389/fonc.2019.01503 · DOI
- Li, 2018, C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells, BMC Canc., 18, 507, 10.1186/s12885-018-4387-5 · DOI
- Lin, 2018, Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells, Breast Canc. Res. Treat., 172, 45, 10.1007/s10549-018-4897-5 · doi:10.1007/s10549-018-4897-5
- Liu, 2019, The correlation between autophagy and tamoxifen resistance in breast cancer, Int. J. Clin. Exp. Pathol., 12, 2066
- Liu, 2009, The critical role of the class III histone deacetylase SIRT1 in cancer, Canc. Res., 69, 1702, 10.1158/0008-5472.CAN-08-3365 · DOI · Paper page
- Lopez-Tarruella, 2007, The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm, Clin. Canc. Res., 13, 6921, 10.1158/1078-0432.CCR-07-1399 · DOI
- Lui, 2016, Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells, BMC Canc., 16, 487, 10.1186/s12885-016-2490-z · DOI
- Lv, 2015, Expression and localization of estrogen receptor in human breast cancer and its clinical significance, Cell Biochem. Biophys, 71, 63, 10.1007/s12013-014-0163-6 · doi:10.1007/s12013-014-0163-6
- Maczis, 2018, Sphingosine kinase 1 activation by estrogen receptor alpha36 contributes to tamoxifen resistance in breast cancer, J. Lipid Res., 59, 2297, 10.1194/jlr.M085191 · DOI
- Mansouri, Clinical evidence on the magnitude of change in growth pathway activity in relation to tamoxifen resistance is required, Curr. Cancer Drug Targets, 18, 668, 10.2174/1568009617666170808110820 · DOI
- Mansouri, A review on the role of VEGF in tamoxifen resistance, Anticancer Agents Med. Chem., 18, 2006, 10.2174/1871520618666180911142259 · doi:10.2174/1871520618666180911142259
- Maqbool, 2020, Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC, Br. J. Pharmacol., 177, 2365, 10.1111/bph.14985 · DOI
- Maynadier, 2016, Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer, Oncol. Rep., 36, 1127, 10.3892/or.2016.4873 · DOI
- Mishra, 2018, Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable Axis for overcoming tamoxifen resistance in ER-positive breast cancer, Clin. Canc. Res., 24, 1987, 10.1158/1078-0432.CCR-17-2776 · DOI
- Nagelkerke, 2014, LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy, Endocr. Relat. Canc., 21, 101, 10.1530/ERC-13-0183 · DOI
- Oh, 2010, Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells, Food Chem. Toxicol., 48, 3227, 10.1016/j.fct.2010.08.028 · DOI
- Omarjee, 2017, The molecular mechanisms underlying the ERalpha-36-mediated signaling in breast cancer, Oncogene, 36, 2503, 10.1038/onc.2016.415 · DOI
- Peng, 2017, Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer, Mol. Canc., 16, 161, 10.1186/s12943-017-0727-3 · DOI · Paper page
- Putluri, 2014, Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance, Neoplasia, 16, 390, 10.1016/j.neo.2014.05.007 · DOI
- Qi, 2017, Sensitization of tamoxifen-resistant breast cancer cells by Z-ligustilide through inhibiting autophagy and accumulating DNA damages, Oncotarget, 8, 29300, 10.18632/oncotarget.16832 · DOI
- Rugo, 2016, Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline, J. Clin. Oncol., 34, 3069, 10.1200/JCO.2016.67.1487 · DOI · Paper page
- Scott, 1998, Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2), Genomics, 48, 330, 10.1006/geno.1997.5190 · DOI · Paper page
- Shen, 2018, Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-alpha36, Oncol. Rep., 39, 2604, 10.3892/or.2018.6350 · doi:10.3892/or.2018.6350
- Shi, 2013, Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features, Int. J. Mol. Sci., 14, 15655, 10.3390/ijms140815655 · DOI
- Shimoda, 2017, Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-beta-hydroxylase expression, Canc. Sci., 108, 2454, 10.1111/cas.13416 · doi:10.1111/cas.13416
- Sun, 2015, Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells, Neoplasma, 62, 199, 10.4149/neo_2015_025 · DOI
- Thomas, 2013, Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt, PLoS One, 8, e68973, 10.1371/journal.pone.0068973 · DOI
- Tong, 2010, ER-alpha36, a novel variant of ER-alpha, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway, PLoS One, 5, e15408, 10.1371/journal.pone.0015408 · DOI
- Vargo-Gogola, 2007, Modelling breast cancer: one size does not fit all, Nat. Rev. Canc., 7, 10.1038/nrc2193 · DOI · Paper page
- Vaziri-Gohar, 2017, IGF-1 receptor modulates FoxO1-mediated tamoxifen response in breast cancer cells, Mol. Canc. Res., 15, 489, 10.1158/1541-7786.MCR-16-0176 · DOI
- Viedma-Rodriguez, 2014, Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review), Oncol. Rep., 32, 3, 10.3892/or.2014.3190 · DOI · Paper page
- Wang, 2020, Effect of aspirin use on neoadjuvant chemoradiotherapy for rectal cancer: a meta-analysis with trial sequential analysis, J. Canc. Res. Clin. Oncol., 146, 2161, 10.1007/s00432-020-03222-w · DOI
- Wang, 2015, Quercetin reverses tamoxifen resistance in breast cancer cells, J BUON, 20, 707
- Wang, 2019, The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy, J. Hematol. Oncol., 12, 81, 10.1186/s13045-019-0747-0 · DOI · Paper page
- Woo, 2016, Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor, Oncotarget, 7, 59809, 10.18632/oncotarget.10999 · DOI
- Wu, 2020, Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway, Int. J. Biol. Sci., 16, 583, 10.7150/ijbs.39936 · DOI
- Xue, 2019, HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer, Br. J. Canc., 121, 1039, 10.1038/s41416-019-0625-0 · DOI
- Ye, 2019, Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer, EMBO Mol. Med., 11, e10638, 10.15252/emmm.201910638 · DOI
- Yin, 2017, GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis, Int. J. Oncol., 51, 1191, 10.3892/ijo.2017.4117 · doi:10.3892/ijo.2017.4117
- Yin, 2014, Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells, PLoS One, 9, e107369, 10.1371/journal.pone.0107369 · DOI
- Yu, 2019, Cell division cycle associated 8 is a key regulator of tamoxifen resistance in breast cancer, J Breast Cancer, 22, 237, 10.4048/jbc.2019.22.e29 · doi:10.4048/jbc.2019.22.e29
- Zhang, 2013, Estrogen receptor-alpha variant, ER-alpha36, is involved in tamoxifen resistance and estrogen hypersensitivity, Endocrinology, 154, 1990, 10.1210/en.2013-1116 · DOI
- Zhang, 2020, Aspirin-targeted PD-L1 in lung cancer growth inhibition, Thorac Cancer, 11, 1587, 10.1111/1759-7714.13433 · DOI
- Zhang, 2018, IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer, Oncogene, 37, 1869, 10.1038/s41388-017-0027-9 · DOI
- Zhu, 2018, Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1, Nat. Commun., 9, 1595, 10.1038/s41467-018-03951-0 · DOI · Paper page
- Zuo, 2011, Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin, J. Cell. Biochem., 112, 2508, 10.1002/jcb.23175 · DOI · Paper page
Cited by
Deng, X., Xie, B., Li, Q., Xiao, Y., Hu, Z., Deng, X., Fang, P., Dong, C., Zhou, H.-B., & Huang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00525 · Cited by 43
Self-citationTakeda, T., Tsubaki, M., Matsuda, T., Kimura, A., Jinushi, M., Obana, T., Takegami, M., & Nishida, S. (2022) · Oncology Reports · doi:10.3892/or.2022.8320 · Cited by 17
Song, T., Zhang, H., Zhao, Q., Hu, Z., Wang, Z., Song, Y., & Zhang, Z. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01790-0 · Cited by 13
Ji, Q.-L., Zeng, Y., Zhou, H., Wang, Q.-B., Zhou, R.-Y., Zhang, J.-J., & Wang, X. (2026) · Scientific reports · doi:10.1038/s41598-026-49617-6 · Cited by 1
“However, a reduction or absence of cytochrome P450 2D6 (CYP2D6) enzyme activity can lead to abnormal metabolism of TAM, resulting in poor therapeutic effect and pharmacological resistance 24–27 .”
Metadata
- Authors
- Yao, J., Deng, K., Huang, J., Zeng, R., & Zuo, J.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-12-09
- Volume
- 11
- Pages
- 592912-592912
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3113117605
- Cited by
- 167
- References
- 2
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer. https://app.cochat.ai/papers/10.3389/fphar.2020.592912
- The paper
- Yao, J., Deng, K., Huang, J., Zeng, R., & Zuo, J. (2020). Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2020.592912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.